2nd Annual Cell and Gene Therapy Manufacturing – Agenda

Day 1: 3 November 2020

13:00
Chairperson’s Opening Remarks


Joint Opening Plenary
Joint Plenary Sessions with 10th Annual Biomanufacturing and 9th Annual Cell Line Development 


13:10
Opening Address:
 
China’s Big Leap towards BioPharma 2030 – Innovation, Industrialization, Internationalization

Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

13:30
Keynote Address:
 
China’s Biologics Facilities for the Future – WuXi’s Story on Technology and Innovation

Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

14:00
Online Networking & Stretch Break


2nd Cell & Gene Therapy Manufacturing commences
China Market


14:20
Chairperson’s Opening Remarks

14:30
Next Generation Cellular Gene Therapeutics

Dr William Cao, Founder, Chairman and CEO, Gracell Biotechnologies Group, China

15:00
Industry Panel:
Regulatory Pathways for Cell and Gene Therapies in the Region, and China 

Panelists:
Richard Wang, CEO, Fosun Kite Biotechnology, China
Dr Zhang Yu, President and CEO, Aeon Therapeutics, China
James Li, Co-Founder and CEO, JW Therapeutics, China
More panellists to be confirmed

15:45
Finding the Market Growth

Richard Wang, CEO, Fosun Kite Biotechnology, China

16:15
Online Networking & Stretch Break

16:40
Addressing the Next Wave of Innovations in Cell Therapies

James Li, Co-Founder and CEO, JW Therapeutics, China

17:10
From Liquid to Solid Tumors, from Manual to Automatic Manufacturing

Dr Zhang Yu, President and CEO, Aeon Therapeutics, China

17:40
Chairperson’s Summary and End of Day 1

Day 2: 4 November 2020

13:00
Chairperson’s Opening Remarks


Joint Opening Plenary
Joint Plenary Sessions with 10th Annual Biomanufacturing and 9th Annual Cell Line Development 


13:10
Manufacturers’ Panel: 
New Therapies, New Tech and New Investment

  • New frontiers in drug development
  • What is the gap in quality and investment?
  • Embracing new tech and start-ups to drive progress
  • New therapeutics manufacturing, commercialization and global access
  • Biomanufacturing 4.0 – Where are we at?
  • DAL’s GAMP and licensing laws – How is it affecting our business and what can we expect?

Panelists:
Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China
Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China (tentatively confirming)
William Cao, Founder, Chairman &CEO, Gracell Biotechnologies Group, China
More panellists to be confirmed

14:00
Online Networking & Stretch Break


2nd Cell & Gene Therapy Manufacturing commences
Technology and Innovation


14:20
Developments in Precision Manufacturing and Tailored Therapies

15:00
Innovations in CAR T-Cell Technology Developments and Manufacturing

For speaking enquiry, please contact Yvonne.Leong@informa.com

15:30
Solid Tumors Treatment with TCR-T Generation

Alex Liu, TCR Discovery and Early Development, Cytovant Sciences, China

15:00
Online Networking & Stretch Break

15:30
Accelerating CAR-T Development and Manufacturing

Yao Shuyuan, General Manager, Wuxi Apptech, China

16:15
Developing Cancer Gene Therapy

16:45
Use of Adenoviruses for Gene Therapy

17:15
Chairperson’s Summary and End of Day 2

Day 3: 5 November 2020

13:00
Chairperson’s Opening Remarks


Joint Opening Plenary
Joint Plenary Sessions with 10th Annual Biomanufacturing and 9th Annual Cell Line Development 


13:10
Keynote Address:
China’s Biopharma Capital Markets – Future Funds and Innovative Financing

Fu Wei, Chief Executive Officer, CBC Group, China

13:30
Venture Capitals’ Roundtable:  
 
Show Me the Drug

  • Investment landscape in the Chinese biopharma market
  • Evaluating drug pipelines and development prospects
  • Mergers, expansion and JVs – Where do we see transactions picking up?
  • Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Moderator:
Fu Wei, Chief Executive Officer, CBC Group, China

Panelists:
Rani Jarkas, Chairman, Cedrus Investments, Hong Kong
Judith Li, Partner, Lilly Asia Ventures, China
Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China
Lynn Yang, Managing Director, Sequoia Capital, China
Dr. John Zhu, Partner, 6 Dimensions Capital, China

14:00
Online Networking & Stretch Break


2nd Cell & Gene Therapy Manufacturing commences
Investments and Commercialisation


14:30
Biotech Investors Roundtable: Financial Incentives, Investments and Pricing 

Panelists:
Kan Chen, Principal, Qiming Weichuang Venture Capital Management, China
More panellists to be confirmed

15:10
Commercialisation Models and Case studies of CAR-Ts


Clinical Trials and Supply Chain


15:40
Efficacy Evidence and Clinical Trials – How They Affect Product Launch and Outcomes-Based Pricing Arrangements

16:10
Online Networking & Stretch Break

16:30
Clinical Drug Development for Cell and Gene Therapies – How Ready Institutions Are?  

17:00
Case Study of Manufacturing and Supply Chain Challenge 

17:30
Chairperson’s Summary and End of Day 3